Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MLYCD | O95822 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543467 | 0.91 | SIGMAR1 (0.46) | SIGMAR1MLYCDEPHX1KDM4CPRMT1 | |
| SCHEMBL2824552 | 0.85 | BCHE (0.36) | EPHX1KDM4CDRD2DRD3ADORA2A | |
| SCHEMBL23613282 | 0.84 | EPHX1 (0.50) | EPHX1DRD2DRD3PRMT1 | |
| SCHEMBL23874511 | 0.82 | EPHX1 (0.54) | SIGMAR1MLYCDEPHX1KDM4C | |
| SCHEMBL12927098 | 0.82 | EPHX1 (0.41) | SIGMAR1MLYCDEPHX1KDM4C | |
| SCHEMBL8070563 | 0.82 | MEN1 (0.38) | EPHX1KDM4CDRD2DRD3PRMT1 | |
| SCHEMBL11150877 | 0.80 | SIGMAR1 (0.40) | SIGMAR1MLYCDEPHX1KDM4C | |
| SCHEMBL11148743 | 0.80 | FAAH (0.37) | EPHX1KDM4CDRD2DRD3PRMT1 | |
| SCHEMBL19303878 | 0.79 | SIGMAR1 (0.42) | SIGMAR1MLYCDEPHX1KDM4C | |
| SCHEMBL13617058 | 0.79 | SIGMAR1 (0.42) | SIGMAR1MLYCDEPHX1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236103-B2 | Bifunctional compounds | BIOTHERYX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | BIOTHERYX, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048277-A1 | BIFUNCTIONAL COMPOUNDS | CDK2, CDK6, CDK5 | SIGMAR1 4656/4885MLYCD 1553/4885EPHX1 3438/4885 |
| US-11236103-B2 | Bifunctional compounds | CDK2, CDK6, CDK5 | SIGMAR1 4656/4885MLYCD 1553/4885EPHX1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.